An impurity of Felypressin. Felypressin is a Vasopressin 1 agonist, and will thus have effects at all Arginine vasopressin receptor 1As. It physiologically effects on vascular SMC's due to the form in which it is administered. Its receptors are found in various sites around the body. The major points include the CNS, Liver, Anterior Pituitary, Muscle (both vascular and non-vascular smooth muscle), and Platelets (CLAMP).
CAT No: 10-101-192
Felypressin Impurity E is a peptide-related compound structurally associated with the synthetic vasoconstrictor peptide felypressin. As a defined impurity, it represents a specific sequence variation or degradation product that may arise during the synthesis, storage, or handling of peptide pharmaceuticals. Its presence is of significant interest in the context of peptide drug development, analytical method validation, and quality control, as understanding and characterizing such impurities is crucial for ensuring the safety, efficacy, and reproducibility of peptide-based products. The study of Felypressin Impurity E enables researchers to deepen their insights into peptide stability, degradation pathways, and the broader landscape of peptide-related substances in pharmaceutical and biochemical research.
Analytical method development: Felypressin Impurity E is frequently employed as a reference standard in the development and validation of analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry. By providing a well-characterized impurity standard, it facilitates the accurate quantification and identification of minor peptide-related components in bulk drug substances and finished formulations. This is essential for establishing robust protocols that can reliably detect and monitor trace-level impurities, thereby supporting regulatory compliance and product quality assurance in peptide manufacturing.
Peptide impurity profiling: In the context of pharmaceutical quality control, this impurity is utilized to construct comprehensive impurity profiles for felypressin and related peptide products. Its inclusion allows scientists to evaluate the presence and proportion of structurally related byproducts that may arise during synthesis or storage. Such profiling is critical for risk assessment, batch release, and the ongoing refinement of synthetic processes, ensuring that the final pharmaceutical preparations meet stringent safety and efficacy standards.
Degradation pathway elucidation: The availability of Felypressin Impurity E enables detailed studies into the degradation mechanisms of peptide drugs. By characterizing how and under what conditions this impurity forms, researchers can map the chemical and physical factors that contribute to peptide instability. These insights inform the optimization of formulation strategies, packaging solutions, and storage conditions, ultimately minimizing the generation of unwanted byproducts throughout the product lifecycle.
Peptide synthesis optimization: The presence of defined impurities such as this one is instrumental in troubleshooting and enhancing peptide synthesis protocols. By monitoring the formation of Felypressin Impurity E during synthetic processes, chemists can identify reaction steps or conditions that favor its generation. This knowledge supports the refinement of synthetic routes, purification methods, and process controls, leading to higher yields of the target peptide and improved overall process efficiency.
Reference material for regulatory submissions: In the context of regulatory filings for new peptide-based pharmaceuticals, having access to characterized impurities is indispensable. Felypressin Impurity E serves as a critical reference material for establishing impurity limits, supporting toxicological assessments, and demonstrating the robustness of analytical methods to health authorities. Its inclusion in regulatory dossiers underscores a commitment to comprehensive impurity characterization and strengthens the scientific foundation of product safety evaluations.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More